<p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>，懷孕公司®（&#34;Sera&#34;或&#34;公司&#34;）（納斯達克：SERA），專注於通過向醫生和患者提供創新的妊娠生物標誌物信息來改善母嬰健康，今天宣佈其承銷的公開發行 1,250,000 股 A 類普通股的定價，公開發行價格為每股 4.00 美元，並且為了某些投資者提供 A 類普通股的替代，預先融資的認股權證可購買 11,250,000 股 A 類普通股，公開發行價格為每個預先融資的認股權證 3.9999 美元，這等於 A 類普通股每股的公開發行價格減去每個預先融資的認股權證的 0.0001 美元行使價格，以上均為承銷折扣和佣金之前的金額。預計此次發行的總收益在扣除承銷折扣和佣金及 Sera 應支付的其他發行費用之前約為 5000 萬美元。Sera 已授予承銷商 30 天的選擇權，以公開發行價格購買最多 1,875,000 股 A 類普通股，扣除承銷折扣和佣金。預先融資的認股權證將立即可行使，並且可以在其原始發行後隨時行使。所有股份和預先融資的認股權證均由 Sera 提供。此次發行預計將在 2025 年 2 月 12 日完成，前提是滿足慣例的交割條件。</p>
<p>Jefferies、TD Cowen 和 William Blair 擔任聯合賬簿管理人，RBC Capital Markets 擔任本次發行的賬簿管理人。</p>
<p>Sera 打算將此次發行的淨收益用於擴大其在美國的商業基礎設施和能力，加快在歐盟擴展的準備工作，資助旨在增加 PreTRM 測試採用率的額外研究，包括可能向美國食品和藥物管理局（&#34;FDA&#34;）提交申請，尋求對 PreTRM 測試的廣泛批准，以及用於一般企業用途。</p>
<p>關於本次承銷發行的證券的貨架註冊聲明（表格 S-3，文件編號 333-281347）已於 2024 年 8 月 7 日向證券交易委員會（&#34;SEC&#34;）提交，並於 2024 年 8 月 13 日獲得有效。此次發行僅通過補充招股説明書和伴隨的招股説明書進行，這些文件構成註冊聲明的一部分。與此次發行相關的初步補充招股説明書和伴隨的招股説明書已提交給 SEC，並可在 SEC 的網站 www.sec.gov 上獲得。與此次發行相關的最終補充招股説明書將提交給 SEC。最終補充招股説明書和伴隨的招股説明書的副本在可用時可從 Jefferies LLC 獲取，注意：股權承銷招股説明書部門，520 Madison Avenue, New York, NY 10022，電話 877-821-7388 或通過電子郵件聯繫 [email protected]；TD Securities (USA) LLC，1 Vanderbilt Avenue, New York, NY 10017，電話 855-495-9846，或通過電子郵件聯繫 [email protected]；或 William Blair &amp; Company, L.L.C.，William Blair 大廈，150 North Riverside Plaza, Chicago, Illinois 60606，電話 (800) 621-0687 或通過電子郵件聯繫 [email protected]。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他管轄區進行這些證券的銷售，除非在該州或其他管轄區的證券法下注冊或資格獲得之前，此類要約、邀請或銷售是非法的。</p>
<p><strong>關於 Sera Prognostics, Inc.</strong></p>
<p>Sera Prognostics 是一家領先的健康診斷公司，致力於通過精準的妊娠護理改善女性和嬰兒的生活。Sera 的使命是提供早期、關鍵的妊娠信息，以改善母親和新生兒的健康，從而降低醫療服務的成本。Sera 擁有一系列創新的診斷測試，專注於早期預測早產風險和其他妊娠併發症。Sera 的精準醫學 PreTRM®測試向醫生報告妊娠中自發性早產的個體化風險，使得對高風險女性進行更早的主動干預成為可能。Sera Prognostics 總部位於猶他州鹽湖城。</p>
<p><strong>安全港聲明</strong></p>
<p>本新聞稿包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”，包括與我們滿足與公開發行相關的慣常成交條件、預期公開發行的成交日期、我們在公開發行中出售證券、預期的總收益金額以及我們對公開發行收益的預期使用相關的聲明。這些 “前瞻性聲明” 基於管理層對未來事件的當前預期，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中所列或暗示的結果存在重大和不利的差異。這些風險和不確定性包括但不限於：與市場條件相關的不確定性以及公開發行是否能夠按預期條款完成，或根本無法完成，淨虧損、現金生成以及可能需要籌集更多資本；PreTRM 測試的收入佔公司迄今為止幾乎所有收入的比例；對 PreTRM 測試的廣泛科學和市場接受的需求；集中數量的主要客户；我們推出新產品的能力；潛在競爭；我們的專有生物庫；關鍵供應商；可尋址市場機會的總估計和市場增長的預測；潛在的第三方支付者覆蓋和報銷；適用於 PreTRM 測試的新報銷方法，包括這些代碼的新 CPT 代碼和支付率；FDA 對實驗室開發測試的監管變化；保護我們測試和市場地位的知識產權；以及在我們向證券交易委員會提交的《10-K 表格年報》和《10-Q 表格季報》中討論的 “風險因素” 標題下的其他因素，以及不時在我們向證券交易委員會提交的定期和當前報告中更新的這些風險因素。本新聞稿中的所有信息均為發佈之日的信息，公司不承擔更新該信息的義務，除非法律要求。</p>
<p>來源：Sera Prognostics, Inc.</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy"/></p>

SERA

<p>Sera Prognostics, Inc. 宣佈以每股 4.00 美元的價格公開發行 1,250,000 股 A 類普通股，並同時發行 11,250,000 股預付認股權證，每股價格為 3.9999 美元。此次發行預計將籌集約 5000 萬美元，所得款項將用於擴展商業基礎設施、為歐盟擴展做準備以及資助 PreTRM 測試的研究。此次發行預計將於 2025 年 2 月 12 日完成，需滿足慣常條件，由 Jefferies、TD Cowen 和 William Blair 擔任聯合賬簿管理人</p>

<p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>, The Pregnancy Company® (&#34;Sera&#34; or the &#34;Company&#34;) (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million. Sera has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of Class A common stock at the public offering price, less underwriting discounts and commissions. The pre-funded warrants will be immediately exercisable, and may be exercised at any time after their original issuance. All of the shares and pre-funded warrants are being offered by Sera. The offering is expected to close on February 12, 2025, subject to the satisfaction of customary closing conditions.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- <strong>Sera Prognostics, Inc.</strong>，懷孕公司®（&#34;Sera&#34;或&#34;公司&#34;）（納斯達克：SERA），專注於通過向醫生和患者提供創新的妊娠生物標誌物信息來改善母嬰健康，今天宣佈其承銷的公開發行 1,250,000 股 A 類普通股的定價，公開發行價格為每股 4.00 美元，並且為了某些投資者提供 A 類普通股的替代，預先融資的認股權證可購買 11,250,000 股 A 類普通股，公開發行價格為每個預先融資的認股權證 3.9999 美元，這等於 A 類普通股每股的公開發行價格減去每個預先融資的認股權證的 0.0001 美元行使價格，以上均為承銷折扣和佣金之前的金額。預計此次發行的總收益在扣除承銷折扣和佣金及 Sera 應支付的其他發行費用之前約為 5000 萬美元。Sera 已授予承銷商 30 天的選擇權，以公開發行價格購買最多 1,875,000 股 A 類普通股，扣除承銷折扣和佣金。預先融資的認股權證將立即可行使，並且可以在其原始發行後隨時行使。所有股份和預先融資的認股權證均由 Sera 提供。此次發行預計將在 2025 年 2 月 12 日完成，前提是滿足慣例的交割條件。</p>
</div><p>Jefferies, TD Cowen and William Blair are acting as joint book-running managers and RBC Capital Markets is acting as a bookrunner for the offering.</p>
<div class="lb-trans"><p>Jefferies、TD Cowen 和 William Blair 擔任聯合賬簿管理人，RBC Capital Markets 擔任本次發行的賬簿管理人。</p>
</div><p>Sera intends to use the net proceeds from the offering to expand its commercial infrastructure and capabilities in the United States, accelerate preparations for expansion in the European Union, fund additional studies designed to increase adoption of the PreTRM test, including a potential submission to the U.S. Food and Drug Administration (the &#34;FDA&#34;) seeking broad approval of the PreTRM test, and for general corporate purposes.</p>
<div class="lb-trans"><p>Sera 打算將此次發行的淨收益用於擴大其在美國的商業基礎設施和能力，加快在歐盟擴展的準備工作，資助旨在增加 PreTRM 測試採用率的額外研究，包括可能向美國食品和藥物管理局（&#34;FDA&#34;）提交申請，尋求對 PreTRM 測試的廣泛批准，以及用於一般企業用途。</p>
</div><p>A shelf registration statement on Form S-3 (File No. 333-281347) relating to the securities offered in the underwritten offering was filed with the Securities and Exchange Commission (the &#34;SEC&#34;) on August 7, 2024 and declared effective on August 13, 2024. The offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC's website located at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to this offering, when available, may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at 877-821-7388 or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at 855-495-9846, or by email at [email protected]; or William Blair &amp; Company, L.L.C., The William Blair Building, 150 North Riverside Plaza, Chicago, Illinois 60606, or by telephone at (800) 621-0687 or email at [email protected].</p>
<div class="lb-trans"><p>關於本次承銷發行的證券的貨架註冊聲明（表格 S-3，文件編號 333-281347）已於 2024 年 8 月 7 日向證券交易委員會（&#34;SEC&#34;）提交，並於 2024 年 8 月 13 日獲得有效。此次發行僅通過補充招股説明書和伴隨的招股説明書進行，這些文件構成註冊聲明的一部分。與此次發行相關的初步補充招股説明書和伴隨的招股説明書已提交給 SEC，並可在 SEC 的網站 www.sec.gov 上獲得。與此次發行相關的最終補充招股説明書將提交給 SEC。最終補充招股説明書和伴隨的招股説明書的副本在可用時可從 Jefferies LLC 獲取，注意：股權承銷招股説明書部門，520 Madison Avenue, New York, NY 10022，電話 877-821-7388 或通過電子郵件聯繫 [email protected]；TD Securities (USA) LLC，1 Vanderbilt Avenue, New York, NY 10017，電話 855-495-9846，或通過電子郵件聯繫 [email protected]；或 William Blair &amp; Company, L.L.C.，William Blair 大廈，150 North Riverside Plaza, Chicago, Illinois 60606，電話 (800) 621-0687 或通過電子郵件聯繫 [email protected]。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的要約邀請，也不應在任何州或其他管轄區進行這些證券的銷售，除非在該州或其他管轄區的證券法下注冊或資格獲得之前，此類要約、邀請或銷售是非法的。</p>
</div><p><strong>About Sera Prognostics, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Sera Prognostics, Inc.</strong></p>
</div><p>Sera Prognostics is a leading health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera's mission is to provide early, pivotal pregnancy information to improve the health of mothers and newborns, resulting in reductions in the costs of healthcare delivery. Sera has a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other complications of pregnancy. Sera's precision medicine PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. Sera Prognostics is headquartered in Salt Lake City, Utah.</p>
<div class="lb-trans"><p>Sera Prognostics 是一家領先的健康診斷公司，致力於通過精準的妊娠護理改善女性和嬰兒的生活。Sera 的使命是提供早期、關鍵的妊娠信息，以改善母親和新生兒的健康，從而降低醫療服務的成本。Sera 擁有一系列創新的診斷測試，專注於早期預測早產風險和其他妊娠併發症。Sera 的精準醫學 PreTRM®測試向醫生報告妊娠中自發性早產的個體化風險，使得對高風險女性進行更早的主動干預成為可能。Sera Prognostics 總部位於猶他州鹽湖城。</p>
</div><p><strong>Safe Harbor Statement</strong></p>
<div class="lb-trans"><p><strong>安全港聲明</strong></p>
</div><p>This press release contains &#34;forward-looking statements&#34; within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our satisfaction of customary closing conditions related to the public offering, the anticipated closing date of the public offering, the sale of our securities in the public offering, the expected amount of the gross proceeds and our anticipated use of proceeds of the public offering. These &#34;forward-looking statements&#34; are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, or at all, net losses, cash generation, and the potential need to raise more capital; revenues from the PreTRM Test representing substantially all Company revenues to date; the need for broad scientific and market acceptance of the PreTRM Test; a concentrated number of material customers; our ability to introduce new products; potential competition; our proprietary biobank; critical suppliers; estimates of total addressable market opportunity and forecasts of market growth; potential third-party payer coverage and reimbursement; new reimbursement methodologies applicable to the PreTRM Test, including new CPT codes and payment rates for those codes; changes in FDA regulation of laboratory-developed tests; the intellectual property rights protecting our tests and market position; and other factors discussed under the heading &#34;Risk Factors&#34; contained in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.</p>
<div class="lb-trans"><p>本新聞稿包含 1995 年《私人證券訴訟改革法案》所定義的 “前瞻性聲明”，包括與我們滿足與公開發行相關的慣常成交條件、預期公開發行的成交日期、我們在公開發行中出售證券、預期的總收益金額以及我們對公開發行收益的預期使用相關的聲明。這些 “前瞻性聲明” 基於管理層對未來事件的當前預期，並受到多種風險和不確定性的影響，這些風險和不確定性可能導致實際結果與前瞻性聲明中所列或暗示的結果存在重大和不利的差異。這些風險和不確定性包括但不限於：與市場條件相關的不確定性以及公開發行是否能夠按預期條款完成，或根本無法完成，淨虧損、現金生成以及可能需要籌集更多資本；PreTRM 測試的收入佔公司迄今為止幾乎所有收入的比例；對 PreTRM 測試的廣泛科學和市場接受的需求；集中數量的主要客户；我們推出新產品的能力；潛在競爭；我們的專有生物庫；關鍵供應商；可尋址市場機會的總估計和市場增長的預測；潛在的第三方支付者覆蓋和報銷；適用於 PreTRM 測試的新報銷方法，包括這些代碼的新 CPT 代碼和支付率；FDA 對實驗室開發測試的監管變化；保護我們測試和市場地位的知識產權；以及在我們向證券交易委員會提交的《10-K 表格年報》和《10-Q 表格季報》中討論的 “風險因素” 標題下的其他因素，以及不時在我們向證券交易委員會提交的定期和當前報告中更新的這些風險因素。本新聞稿中的所有信息均為發佈之日的信息，公司不承擔更新該信息的義務，除非法律要求。</p>
</div><p>SOURCE Sera Prognostics, Inc.</p>
<div class="lb-trans"><p>來源：Sera Prognostics, Inc.</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwMjEwJk5ld3NJdGVtSWQ9TEExNjM0MiZUcmFuc21pc3Npb25fSWQ9MjAyNTAyMTAyMjQxUFJfTkVXU19VU1BSX19fX19MQTE2MzQy" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA16342&amp;Transmission_Id=202502102241PR_NEWS_USPR_____LA16342&amp;DateId=20250210"/></p>

Sera Prognostics 宣佈 5000 萬美元公開發行的定價